Replies to post #153397 on Biotech Values

[oc631]

GS-5885, as far as i can tell, is not active in genotypes 2 and 3

That's what Norbert said. Do you have a link? Is it the class or just GS-5885?

[mcbio]

GS-5885, as far as i can tell, is not active in genotypes 2 and 3

It's not active in GT2? I wonder if that might be good news for Medivir since I believe simeprevir is active in GT2, just not GT3. I wonder if GILD may be open to combos with external HCV drugs to treat GT2/GT3.

For ACHN and IDIX, I think their best chance to compete in the next gen HCV treatment paradigm is to have clear activity beyond GT1, particularly GT3. That seems to be a clear opportunity. I think it's too crowded and they're too far behind to compete meaningfully in GT1.

[genisi]

GS-5885, as far as i can tell, is not active in genotypes 2 and 3

Indeed it is less potent against GT2/3 in replicon assays I've seen (don't recall clinical data), but data from phase II of sofosbuvir/daclatasvir regimen were quite good in GT2/3:

http://mobile.ilcapp.eu/EASL_161/poster_24858/program.aspx

So, I think it's quite possible that GILD's NS5A GS-5885 can produce similar results.

Edit: just kept reading and seen the following posts on the issue but I'll leave mine just because it has the link to the EASL poster...